Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective
Conclusions
Ranibizumab provides greater health gains at a lower overall cost than aflibercept in the treatment of visual impairment due to macular edema secondary to BRVO. Ranibizumab is therefore cost-effective from a UK healthcare payer’s perspective.
Funding
Novartis Pharma AG, Basel, Switzerland
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Eyes | Health | Lucentis | Pharmaceuticals | Ranibizumab Injection | Study